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The Journal of Immunology
Molecular and Functional Characterization of Mouse
S5D-SRCRB: A New Group B Member of the Scavenger
Receptor Cysteine-Rich Superfamily
Cristina Miro´-Julia`,*,1 Sandra Rosello´,†,1 Vanesa G. Martı´nez,* Dorte R. Fink,‡
Cristina Escoda-Ferran,* Olga Padilla,† Citlali Va´zquez-Echeverrı´a,x Paula Espinal-Marin,{
Cristina Pujades,x Angeles Garcı´a-Pardo,‖ Jordi Vila,{ Carles Serra-Page`s,†,#
Uffe Holmskov,‡ Jose´ Ye´lamos,** and Francisco Lozano†,#
The scavenger receptor cysteine-rich superfamily (SRCR-SF) members are transmembrane and/or secreted receptors exhibiting
one or several repeats of a cysteine-rich protein module of ∼100 aa, named scavenger receptor cysteine-rich (SRCR). Two types of
SRCR domains (A or B) have been reported, which differ in the number of coding exons and intradomain cysteines. Although no
unifying function has been reported for SRCR-SF members, recognition of pathogen-associated molecular patterns (PAMPs) was
recently shown for some of them. In this article, we report the structural and functional characterization of mouse S5D-SRCRB,
a new group B member of the SRCR-SF. The s5d-srcrb gene maps at mouse chromosome 7 and encompasses 14 exons extending
over 15 kb. The longest cDNA sequence found is 4286 bp in length and encodes a mature protein of 1371 aa, with a predictedMr of
144.6 kDa. Using an episomal mammalian-expression system, a glycosylated soluble recombinant form >200 kDa was obtained
and used as immunogen for the generation of specific rat mAbs. Subsequent immunohistochemical and real-time PCR analysis
showed significant S5D-SRCRB expression in murine genitourinary and digestive tracts. S5D-SRCRB was shown to bind endog-
enous extracellular matrix proteins (laminin and galectin-1), as well as PAMPs present on Gram-positive and Gram-negative
bacteria and fungi. PAMP binding by S5D-SRCRB induced microbial aggregation and subsequent inhibition of PAMP-induced
cytokine release. These abilities suggest that S5D-SRCRB might play a role in the innate defense and homeostasis of certain
specialized epithelial surfaces. The Journal of Immunology, 2011, 186: 2344–2354.
T
he innate immune system represents the first line of host
defense for multicellular organisms to maintain homeo-
stasis of the internal environment against foreign patho-
gens (microorganisms, chemicals), as well as altered self-com-
ponents (1). To do this, the humoral (i.e., complement) and the
cellular (e.g., mucocutaneous barriers, macrophages) arms of the
innate immune system are equipped with a set of inborn (germ-
line encoded) receptors named pattern recognition receptors
(PRRs). These PRRs recognize a relatively small spectrum of
highly conserved structures of protein, saccharide, lipid, and nu-
cleic acid nature of endogenous and exogenous origin. Typically,
PRRs recognize pathogen-associated molecular patterns (PAMPs),
which are conserved components essential for pathogen surviv-
al and are not shared by the host. Examples of PAMPs include
LPS from Gram-negative bacteria, lipotheicoic acid (LTA) and
peptidoglycan (PGN) from Gram-positive bacteria, dsRNA from
virus, lipoarabinomannan from mycobacteria, and mannan and
b-glucan from fungi. Recognition of PAMPs by PRRs usually
initiates an inflammatory cascade that involves recruitment of
leukocytes to the site of infection, activation of antimicrobial ef-
fector mechanisms, and induction of adaptive immune responses
that promote clearance of infection and long-term immune mem-
ory. In this way, the mammalian immune system eliminates in-
vading pathogens with maximal efficacy and minimal damage to
self (2). There are two main groups of PRRs: secreted molecules
that circulate in blood and lymph and cell-surface receptors
present on hemopoietic and epithelial cells. Each group is formed
by several classes of PRRs, which have emerged and coevolved
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independently, giving rise to structurally and functionally different
molecules, although with cooperative and complementary de-
fensive and homeostatic functions. Examples of PRRs include
proteins with leucine-rich repeats (i.e., TLRs), C-type lectin do-
mains (i.e., dectin-1, DC-SIGN), and scavenger receptors (i.e., SR-
AI/II, CD36, MARCO).
The scavenger receptor cysteine-rich superfamily (SRCR-SF) is
an ancient and highly conserved group of membrane-bound and/or
soluble proteins mostly reported in the animal kingdom, from low
invertebrates to mammals (3–5), as well as in some aquatic plants
[i.e., unicellular green alga (6)]. In mammals, SRCR-SF members
can be expressed by hemopoietic and nonhemopoietic cells, at
embryonic and adult developmental stages, depending on species
and tissue type. These proteins were reported to play a role in the
regulation of innate and adaptive immune responses, as well as in
the development of the immune system (3–5). Members of the
SRCR-SF are characterized by the presence of one or several
repeats of a highly conserved cysteine-rich extracellular scavenger
receptor cysteine-rich (SRCR) domain (∼100–110 aa in size),
which was first reported on the mouse macrophage scavenger re-
ceptor type I (SR-AI) (7). Depending on the number of cysteine
residues present in the SRCR domain and the number of exons
coding for each domain, the SRCR-SF can be divided into two
mutually exclusive groups: A and B. Group A contains SRCR do-
mains encoded by two or more exons and including six cysteines
forming three disulphide bonds, whereas group B domains are
encoded by a single exon and contain eight cysteines forming four
disulphide bonds (3–5).
The extracellular regions of SRCR-SF members may present as
exclusively composed of SRCR domains repeated in tandem or as
multidomain mosaic proteins in which the SRCR domains seem to
be combined with other types of protein modules, such as epithe-
lial growth factor, C1r/C1s Uegf Bmp1, zona pellucida, collage-
nous regions, fibronectin, and short consensus repeats. The pres-
ence of short Pro, Ser, and Thr (PST)-rich polypeptides interspaced
with contiguous SRCR domains is also frequently observed among
SRCR-SFmembers. Available three-dimensional structures obtained
from crystallization experiments indicate that group A and B SRCR
domains present a highly conserved and compact core folding (a
curved six-stranded b sheet cradling an a helix) with variable outer
loop regions, likely giving rise to functional diversity (8–13).
Despite the overall structure conservation of the SRCR domains
across different species, no unifying biological function has been
reported. They do not possess enzymatic activity; however, some
SRCR domains have been involved in protein–protein interactions,
the best studied examples being those of CD6 with CD166/ALCAM
(4) and CD163 with the haptoglobin–hemoglobin complex (14). In
recent years, a number of studies also supported the recognition of
PAMPs by some, but not all, group A (i.e., MARCO) (15) and B
(i.e., DMBT1/SAG/gp340, Spa, CD6, CD5, and CD163) (16–20)
SRCR-SF members. Group B is composed of about a dozen mem-
bers expressed in mammals by immune cells, such as macrophages
(i.e., CD163/M130, CD163L1/M160, Spa/AIM) or lymphocytes
(i.e., CD5, CD6, SCART, WC1), as well as by cells of the gastro-
intestinal, respiratory, and genitourinary tracts (i.e., DMBT1/
SAG/gp340, S4D-SRCRB, 18-B) (5, 21). The present work
reports on the characterization, at the molecular and functional
levels, of S5D-SRCRB (soluble 5 domain SRCR type B), the mouse
homolog of a recently cloned human soluble member belonging to
group B of SRCR-SF (SSc5D), for which no biochemical and
functional data are available (22). By generating a recombinant
protein form and a set of specific mAbs, we showed that mouse
S5D-SRCRB is a secreted glycoprotein with a restricted tissue-
expression pattern (mainly cells of the genitourinary and digestive
tracts), which is able to bind to endogenous extracellular matrix
components (laminin, galectin-1), as well as to constitutive com-
ponents of bacterial (Gram-negative or -positive) and fungal (sap-
rophytic and pathogenic) surfaces. These data argue in favor of
mouse S5D-SRCRB being a component of the humoral arm of the
innate immune system likely involved in the defense and homeo-
stasis of host epithelial surfaces.
Materials and Methods
Reagents
PBS (Roche Diagnostics, Mannheim, Germany) contained 137 mMNaCl, 3
mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4 (pH 7.4). TBS contained 50
mM Tris-HCl (pH 7.4), 140 mM NaCl. Radioimmunoprecipitation assay
(RIPA) buffer contained 50 mM Tris (pH 8), 150 mM NaCl, 1% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% SDS supplemented with complete
protease inhibitors (Roche Diagnostics), and 1 mM Na3VaO4.
Cell lines
The human embryonic kidney cell line HEK 293-EBNA, which stably
expresses the EBNA-1 Ag from EBV, was kindly provided by Takako
Sasaki (Max-Planck-Institut fu¨r Biochemie, Martinsried, Germany). HEK
293 cells stably expressing TLR2 were a kind gift from Dr. Golenbock
(University of Massachusetts Medical School, Worcester, MA). HEK 293-
EBNA cells were grown in DMEM/F12 (Life Technologies Life Science,
Grand Island, NY) supplemented with antibiotics (100 U/ml penicillin, 100
mg/ml streptomycin), 10% heat-inactivated FCS (Walkersville, MD), and
250 mg/ml Geneticin (Life Technologies).
Identification and genomic characterization of s5d-srcrb
Bioinformatic tools available in public databases (http://www.ncbi.nlm.nih.
gov) were used to search for new members of group B of the SRCR-SF.
The high-throughput genome sequences and the nonredundant database
sections of GenBank (http://www.ncbi.nlm.nih.gov/Genbank) were screened
using the TBLASTN algorithm with the protein sequences of CD5 and
CD6 as templates (Acc. No. XO4391 and U34623, respectively). Mouse
genomic clones with significant similarities (Evalue , 10210) were selected
and analyzed through the BLASTN algorithm against the mouse expressed
sequences tagged (ESTs) database of GenBank. The ESTs or full-length
clones of interest were obtained from distribution centers already cloned
into pFLCI and were further sequenced in both directions with the ABI
PRISM dRhodamine terminator Cycle Sequencing Ready Reaction kit (PE
Applied Biosystems, Warrington, U.K.) using universal M13 primers
(M13-20.Fw 59-GTAAAACGACGGCCAGT-39; M13.Rv 59-AACAGC-
TATGACCATG-39). The AK079906 or A430110N23 full-length cDNA
sequences (gi: 26348280) were used for mouse chromosome mapping
of s5d-srcrb (http://www.ncbi.nlm.nih.gov/mapview). Similarly, determina-
tion of exon/intron boundaries was done by alignment of AK079906
with the mouse genomic sequence AC0794876 (gi: 9964851) using the
BLAST2 tool (http://www.ncbi.nlm.nih.gov/BLAST).
Cloning and expression of s5d-srcrb
The full-length cDNA of s5d-srcrb tagged with a C-terminal hemagglutinin
(HA) sequence was cloned into a modified version of the pCEP-Pu/AC7
mammalian expression vector (kindly provided by Takako Sasaki, Max-
Planck-Institut fu¨r Biochemie). To this purpose, the AK079906 full-length
cDNA sequence was used as a template for PCR amplification (Taq Ex-
pand High Fidelity Polymerase System; Roche Diagnostics) with the spe-
cific primers msd1.Fw (59-CCCAAGCTTTCAGCAGCTGCTTCCCTC-
CCT-39) and msd2.Rv (59-GAAGATCTCACATCTCCCCTCAGAGGC-
CT-39) containing HindIII and BglII restriction sites, respectively (under-
lined). The cycling conditions were one step of 95˚C for 5 min; 35 cycles
of 95˚C for 45 sec, 63˚C for 45 sec, and 72˚C for 4 min 30 sec; and a final
extension step of 72˚C for 10 min. The resulting PCR product was purified
(PCR purification kit, Qiagen, Hilden, Germany) and then digested with
HindIII and BglI (MBI Fermentas, Glen Burnie, MD). The restricted pro-
duct was gel purified (QIAquick Gel Extraction Kit, Qiagen) and cloned
into an appropriately digested (HindIII and BamHI) pCep-Pu/AC7-HAtag
vector using the T4 DNA Ligase (Takara, Shiga, Japan). The ligation
products were transformed into DH5a Escherichia coli-competent cells,
and the resulting clones were checked by sequencing in both di-
rections with vector-specific primers and the Prism Ready Reaction Big
Dye Deoxy Terminator sequencing kit (PE Applied Biosystems). HEK293-
EBNA cells were transfected with the above-mentioned construct using
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Lipofectamine 2000 reagent (Invitrogen, Paisley, U.K.), according to the
manufacturer’s protocol. Transfectants were selected 48 h later in DMEM/
FCS/Geneticin plus 1 mg/ml Puromycin (Sigma, St. Louis, MO) and left to
grow to confluence. To perform protein-expression analysis, confluent
transfectants were cultured in serum-free DMEM/F12 medium (without
selecting antibiotics), and supernatants were collected every 48–72 h;
storage of supernatants was at 220˚C after supplementation with 0.5 mM
PMSF, 0.02% sodium azide, and 2.5 mM EDTA. Supernatant samples (1.5
ml) were precipitated with TCA and run over 6–8% SDS-PAGE under
reducing conditions, followed by electrotransfer to nitrocellulose mem-
branes (Bio-Rad Laboratories, Richmond, CA). For Western blot analysis,
membranes were blocked for 1 h at room temperature with PBS containing
10% nonfat milk and then incubated with a mouse anti-HA mAb (cat. #sc-
7392; Santa Cruz, Santa Cruz, CA). After extensive washing with PBS
0.01% Tween20, membranes were further incubated with a 1:1000 dilution
(in blocking buffer) of HRP-conjugated sheep anti-mouse IgG (Amersham
Biosciences, Fairfield, CT). Blots were visualized by chemiluminescence
with Supersignal West Dura Extended Duration Solution (Pierce, Rock-
ford, IL).
Real-time retrotranscription quantitative PCR assays
Analysis of the expression pattern of s5d-srcrbwas performed in C57BL/6J
mouse tissues by real-time retrotranscription quantitative PCR (RT-qPCR)
analysis. Total RNA was extracted using the TRIzol reagent method, as
recommended by the manufacturer (Invitrogen). cDNA synthesis was per-
formed using the GeneAmp PCR kit (Roche). Briefly, 0.5–1 mg total RNA
was mixed with 2.5 mM oligo-d(T)16 primer, 1 mM 29-deoxynucleoside 59-
triphosphates, 13 PCR Buffer II, and 5 mM MgCl2. After denaturing for 5
min at 65˚C, 20 URNase inhibitor and 50UMoloneymurine leukemia virus
reverse transcriptase were added (total reaction volume, 20ml). The reaction
was incubated for 90 min at 42˚C and stopped for 15 min at 99˚C. cDNA
integrity was checked by PCR using primers specific for the housekeeping
18S gene (18S.Fw: 59-AAACGGCTACCACATCCAAG-39 and 18S.Rv: 59-
CCTCCAATGGATCCTCGTTA-39) and s5d-srcrb gene (mS5D.Fw: 59-
AAGACGTGGTGCTCACCTGC-39 and mS5D.Rv: 59-TCCCACGTCCAG-
GAAGACTC-39) using the following cycling conditions: 2 min at 93˚C,
followed by 30 cycles of 93˚C for 45 s, 56˚C for 45 s, and 72˚C for 5min. For
RT-qPCR, the same s5d-srcrb and 18S gene-specific primers were used in
a reaction mixture of cDNA (2 ml; 1:100 diluted) and LightCycler FastStart
DNA Master SYBR Green I mix (Roche Diagnostics). Reactions were
carried out on an ABI 7900HTT FastReal Time PCR System (Applied
Biosystems) under the following cycling conditions: 10 min at 95˚C, 40
cycles of 95˚C for 15 s, and 60˚C for 1min. Gene expression was normalized
to 18S and expressed in arbitrary units.
Generation of rat anti–S5D-SRCRB mAbs
For immunization purposes, each Sprague-Dawley rat was injected i.p.
fortnightly with TCA precipitates from 12 ml FCS-free supernatant samples
of recombinant HA-tagged mouse S5D-SRCRB (rmS5D-SRCRB-HA)-
producing stable HEK 293-EBNA transfectants. In brief, FCS-free su-
pernatant was precipitated in 14% TCA and 0.14% Triton X-100 for 10 min
on ice and then pelleted at 14,000 rpm for 30 min at 4˚C, washed with cold
acetone, and resuspended with PBS. The first dose of Ag was emulsified
with CFA (Sigma), and the next two immunizations were emulsified with
IFA (Sigma). The spleen was removed at day 3 after i.v. injection of the Ag
without adjuvant, and cells were fused with the non-Ig–secreting myeloma
X63-Ag8.653 using polyethylene glycol 1500 (Sigma) (23). Hybridomas
were selected by growth in RPMI 1640 culture medium (Cambrex Bio-
science, Walkersville, MD) containing hypoxanthine, aminopterin, and
thymidine (10) (Sigma) and supplemented with 12% FCS (Life Technol-
ogies, Invitrogen), 2 mM glutamine (Life Technologies, Invitrogen), 1 mM
pyruvate (Sigma), 100 U/ml penicillin, and 100 mg/ml streptomycin.
Hybridoma cell supernatants were analyzed by ELISA using plates coated
with FCS-free rmS5D-SRCRB-HA supernatants and HRP-conjugated goat
anti-rat IgG antiserum (Sigma). Anti–rmS5D-SRCRB-HA–reactive hybrid-
omas were subcloned twice by limiting dilution after discarding their re-
activity against the HA tag. The immunoreactivity of the mAb obtained
was analyzed by different immunochemical techniques (immunoprecipi-
tation, ELISA, and Western blot).
Western blot detection of mouse S5D-SRCRB in cell
transfectants and tissues
Tissue samples from C57BL/6J males were snap-frozen in liquid nitrogen
and then weighed, minced, and mixed with three volumes of RIPA lysis
buffer for homogenization with a Teflon-glass Dounce, followed by soni-
cation with two short bursts (2 s) in a Barnson Sonifier 250 (Danbury, CT).
Tissues were kept on ice for 20 s in between bursts. After clarification at
12,000 rpm for 20 min at 4˚C, total protein content from supernatants was
quantified by the Bradford method (BCA Protein assay kit; Pierce), as
recommended by the manufacturer. For control purposes, 1 3 107 HEK
293-EBNA transfectants expressing rmS5D-SRCRB-HA were lysed fol-
lowing the same procedure. Protein samples (100 mg) were resolved by 6–
7.5% SDS-PAGE and then electrotransferred to a nitrocellulose membrane
(BioRad, Durham, NC). Subsequently, Western blot analysis was per-
formed using a 1:2 dilution of rat 1H11.A8.G2 hybridoma supernatant plus
goat HRP-conjugated anti-rat IgG (Sigma), as previously described.
Deglycosylation assays
The rmS5D-SRCRB-HA was immunoprecipitated using serum-free rat
anti–S5D-SRCRB 1H11.A8.G2 hybridoma supernatant previously adsor-
bed for 1 h at 4˚C under orbital rotation with 50 ml a 50% (v/v) suspension
(in PBS) of Protein G Sepharose 4 Fast Flow (GE Healthcare, Uppsala,
Sweden). The beads were pulled down, washed three times with PBS, and
incubated with serum-free rmS5D-SRCRB-HA supernatant for 1 h at 4˚C
under gentle rotation. The beads were washed again, as before, and treated
with different glycosidase combinations from the Enzymatic Protein
Deglycosylation Kit (Sigma), following the manufacturer’s instructions.
The resulting products were resolved by SDS-PAGE and analyzed by
Western blot, as described above.
Bacterial and fungal protein-binding assays
E. coli ATCC25922 and Staphylococcus aureus ATCC29213 were obtained
from the American Type Culture Collection. Schizosaccharomyces pombe
and Saccharomyces cerevisiae were kindly provided by the Cell Biology
Unit of the University of Barcelona. The rest of the bacterial and fungal
strains used in this study are clinical isolates characterized by the De-
partment of Microbiology, Hospital Clinic of Barcelona, using standard
biochemical procedures. Bacteria were grown overnight at 37˚C in Luria-
Bertani medium, and fungi were grown at 28˚C in Sabouraud’s medium
with aeration, harvested by centrifugation at 3500 rpm for 10 min, and
resuspended in TBS to a final density of 1010 bacteria/ml or 108 fungi/ml.
Aspergillus fumigatus was grown at 30˚C in Sabouraud’s for 1 wk, and the
cells were resuspended in TBS to a final DO530nm = 0.2, which corresponds
to a final density of 108 fungi/ml. Under these conditions, the cell suspension
was a mixture of mainly conidiophores, conidia, and filaments. Quantifi-
cation was performed by plating bacteria and fungi dilutions on agar. For
microbial-binding assays, aliquots ∼5 3 107 bacteria and ∼5 3 106 fungi
were incubated for 1 h at 4˚C under gentle orbital rotation with different
amounts of serum-free supernatant from HEK 293-EBNA transfectants
expressing rmS5D-SRCRB-HA in binding buffer (TBS plus 1% BSA and 5
mM CaCl2) to a final volume of 0.5 ml. In parallel, 100 ml testis and liver
lysates was incubated with ∼5 3 107 Gram-positive bacteria (S. aureus) in
binding buffer to a final volume of 0.5 ml by gentle orbital rotation for 1 h at
4˚C. The lysates were obtained from 95 mg tissue samples, minced, and
mixed with three volumes of binding buffer for homogenization with
a Teflon-glass Dounce, followed by sonication with two short bursts in
a Branson Sonifier 250. Following incubation, microbial cells were pelleted
and washed once with 0.5 ml binding buffer and twice with 0.5 ml TBS plus
5 mM CaCl2 to remove nonspecifically bound proteins. The washed pellets
were resuspended in reducing Laemmli’s sample buffer for 15 min at 100˚C
and separated on 6–7.5% SDS-PAGE gels, followed by electrotransfer to
a nitrocellulose membrane (BioRad). Membranes were subjected to West-
ern blot analysis, as described above. Aggregation assays were performed
using fresh overnight cultures of E. coli, Acinetobacter baumannii, S. au-
reus, and Candida albicans harvested by centrifugation at 3500 rpm for 10
min and then resuspended in PBS to a final density of 1010 bacteria or 108
fungi per ml. FITC (Sigma) was dissolved in PBS to a concentration of 10
mM and then added to the bacterial/fungal suspensions to a final concen-
tration of 1 mM for 30 min at room temperature. Following removal of
excess unbound FITC by extensive washing with PBS, 10 ml FITC-labeled
bacterial/fungal suspension (5 3 107 bacteria and 5 3 106 fungi) in TBS
containing 5 mM CaCl2 was incubated overnight at room temperature with
20 mg/ml affinity-purified rmS5D-SRCRB-HA or BSA. Then, 10 ml the
samples was examined by fluorescence microscopy.
Galectin 1 protein-binding assay
The plasmid used for bacterial expression of GST-Galectin 1 (GST-Gal1)
was kindly provided by Dr. Fu-Tong Liu (UC Davis, Davis, CA). Overnight
cultures of transformed BL21 E. coli cells were diluted 1:10 in 500 ml
Luria-Bertani broth supplemented with ampicillin (0.1 mg/ml) and grown
for ∼4 h at 37˚C until OD600nm ∼0.8. Then, expression of GST-Gal1 was
induced by the addition of isopropyl b-D-1-thiogalactopyranoside (0.1
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mM) for an additional 4 h. The bacterial cell pellet was subjected to three
cycles of freezing/thawing and was sonicated and solubilized with 10%
Triton X-100 in the presence of protease inhibitors (Complete; Roche).
The clarified supernatant was mixed with Glutathione Sepharose 4B beads
(GE Healthcare) for 2 h at 4˚C under gentle orbital rotation. The beads
were then washed thoroughly with TBS 1% Triton X-100, resuspended in
TBS, and kept at 4˚C until used. GST-Gal1–Sepharose beads were in-
cubated for 90 min at 4˚C in blocking buffer (TBS plus 5% BSA). Then, 10
ml 50% (v/v) beads were incubated overnight at 4˚C with 25 ml serum-free
rmS5D-SRCRB-HA–containing supernatants in the presence or absence of
increasing concentrations (3, 15, 30 mM) of competing sugars (lactose or
sucrose). Beads were washed twice with TBS 0.01% Tween 20 and once
with TBS alone to remove unbound protein. The proteins were eluted with
Laemmli’s sample buffer and separated on SDS-PAGE under reducing
conditions for further Western blot analysis.
ELISA assays
Interaction of rmS5D-SRCRB-HAwith PAMP was analyzed by coating 96-
wellmicrotiter plates (Nunc,Roskilde,Denmark) overnight at 4˚Cwith 2mg/
well purified LPS from E. coli K12 (InvivoGen, San Diego, CA), PGN (cat.
#77140; Sigma), LTA from S. aureus (cat. #2515; Sigma), Zymosan A (cat.
#z4250; Sigma), glucan from bakers’ yeast (cat. #g5011; Sigma), b(1→3)-
glucan (cat. #89862; Sigma), b-D-glucan (cat. #g6513; Sigma), or mannan
(cat. #m7504; Sigma) in coating buffer (100 mM NaHCO3 [pH 9.5]). Non-
specific binding to plastic wells was prevented by incubation for 1 h at room
temperature in blocking solution (PBS plus 3%BSA). Serial 2-fold dilutions
of serum-free rmS5D-SRCRB-HA supernatants were added to thewells and
incubated for 2 h at room temperature. Bound protein was detected by a 1-h
incubation at room temperature with neat serum-free 1H11.A8.G2 rat hy-
bridoma supernatant, followed by a 30-min incubationwith a 1:1000 dilution
of goat anti-rat IgG/HRP antiserum (Sigma). Between each incubation step,
excess unboundproteinswerewashed off three timeswith PBS0.01%Tween
20. Color was developed by adding 3,39,5,59-tetramethylbenzidine (TMB)
liquid substrate (Sigma), and the absorbance was measured at 450 nm. The
assay was repeated twice with similar results.
Interaction of rmS5D-SRCRB-HAwith extracellular matrix proteins was
analyzed by coating ELISA microtiter plates overnight at 4˚C with 0.5 mg/
well purified fibronectin, laminin, collagen I, and collagen IV (supplied by
Angeles Garcı´a-Pardo, Centro de Investigaciones Biolo´gicas-Centro Su-
perior de Investigaciones Cientı´ficas, Madrid) in PBS (Roche). The assay
conditions were the same as described above, with the exception that in-
cubations were performed at 4˚C, and the 4D11.A2.H4 hybridoma super-
natant was used for detection purposes. The assay was repeated twice with
similar results.
Immunohistochemical assays
Four-micrometer sections from neutral-buffered formaldehyde-fixed paraffin-
embedded tissue blocks were mounted on ChemMate Capillary Gap
Slides (Dako, Glostrup, Denmark), dried at 60˚C, deparaffinized, and hydra-
ted. Prior to Ag retrieval, blocking of endogenous peroxidase was per-
formed in 1.5% hydrogen peroxide in TBS buffer (pH 7.4) for 10 min. Ag
retrieval was carried out using microwave heating in target retrieval solution
(Dako) or pepsin. Three Tissue-Tek containers (Miles, Elkhart, IN), each
with 24 slides in 250 ml buffer, were placed on the edge of a turntable inside
themicrowave oven. Slideswere heated for 11min at full power (900W) and
then for 15 min at 400W. After heating, slides were left in buffer for 15 min.
Incubationwith 1:10 diluted supernatants (in AbDiluent S2022; Dako) from
anti–S5D-SRCRB hybridomas (1H11.A2.G8, 4D11.A2.H4, 8F4.F3.F9,
5B7.B8.A1, 8C11.D6.C9, 7G4.E1.H7, and 5E12.G3.B1) was carried out for
60min at room temperature. No immunostainingwas seenwhen the primary
Ab was omitted or substituted with an isotype control. Immunostaining was
automated using the PowerVision+ HRP detection system DPVB+500HRP
(ImmunoVision Technologies, Brisbane, CA) on the TechMate 500 in-
strument (Dako). DAB+ (K3468; Dako) was used as substrate-chromogen
system. Immunostaining was followed by brief nuclear counterstaining in
Mayer’s hematoxylin. Finally, cover slips were mounted with AquaTex
(Merck, Darmstadt, Germany).
IL-8–release assay
HEK 293 cells and HEK 293 cells stably expressing TLR2 were plated on
a 96-well plate at a density of 53 104 cells/well for 24 h and then cultured
in serum-free media for an additional 24 h. Cells were then pulsed with 20
mg/ml PGN for 24 h in the presence of supernatants from HEK 293-EBNA
transfectants expressing rmS5D-SRCRB-HA or from untransfected cells as
a control. Culture supernatant samples (25 ml) were collected and assayed
for human IL-8 by ELISA (BD OptEIA, Human IL-8 ELISA Set; BD
Biosciences, San Diego, CA), following the manufacturer’s instructions.
Results
Identification and cloning of mouse s5d-srcrb
The screening of GenBank databases with the CD5 and CD6 pro-
tein sequences rendered two Mus musculus P1-derived artifi-
cial chromosome genomic clones (Acc. No. AC079486 and
AC079542) predicted to contain a gene coding for a protein contain-
ing several group B SRCR domains. Also identified were 69 EST
clones with significant similarities (Evalue, 10210) to PAC geno-
mic clones, 17 of which showed the highest score (Supplemental
Table I) and were expressed in different tissues (muscle, brain, mam-
mary gland, pancreas, liver, eye, gastrointestinal tract) and at
different developmental stages (from embryo to adult). Two
4286 bp-long cDNA clones (Acc. No: AK079906 and A430110-
N23) obtained from thymus tissue of C57BL/6J mice at day
0 of neonatal development were cloned into the pFLCI vector to
be fully resequenced. They were shown to contain an open reading
frame of 4116 bp encoding a polypeptide chain of 1371 aa (Acc.
No: BAC37780 and NP_766596), with a predictedMr of 144.6 kDa
(Supplemental Fig. 1). This putative new protein (Acc. No:
EU850434, gi: 194354452) contained a short leader peptide and
five SRCR domains (each was ∼100 aa in size) (http://www.ncbi.
nlm.nih.gov/structure/cdd). The N-terminal signal peptide se-
quence was 16 aa long, and the most likely signal peptidase
cleavage site was IQA-IE (Signal IP 3.0; http://www.cbs.dtu.dk).
Four Asn-X-Ser/Thr motifs were found, three of which (NETA,
NSTA, and NTTS) are predicted to be N-glycosylated (NetNGlyc
1.0; http://www.cbs.dtu.dk). All five SRCR domains fulfilled the
characteristics of group B (encoded by a single exon and containing
eight properly spaced cysteines) (5) and were interspersed by short
(between SRCR1–SRCR2, and SRCR3–SRCR4), intermediate
(between SRCR4–SRCR5), or long (C-terminal to SRCR5) PST-
rich regions. Multiple O-glycosylation sites were predicted, which
were mainly located within the PST-rich sequences (NetOGlyc 3.1;
http://www.cbs.dtu.dk) (Fig. 1A, 1B). The PST-rich region C-
terminal to SRCR5 was predicted to contain a 155-aa-long se-
quence (from aa 1050–1205) with homology to syndecan domains
(http://www.ncbi.nlm.nih.gov/structure/cdd). No transmembrane
region could be predicted (TMHMM; http://www.cbs.dtu.dk), as
would be expected for a secreted protein. The mouse gene encoding
this cDNA sequence was named s5d-srcrb, for soluble protein with
5 domains of the SRCR group B, and was mapped to chromosome 7
(http://www.ncbi.nlm.nih.gov/mapview). It spans 15 kb and
encompasses 14 exons (Fig. 1A). Exons 1 and 2 encode the 59-
untranslated region and the signal peptide. Exons 3, 6, 7, 9, and 11
encode each of the five SRCR domains as expected for group B
members. Exons 4, 5, 8, and 10 encode the short and intermediate
PST-rich intervening regions. Exons 12–14 encode the long PST-
rich C-terminal region (encompassing the putative syndecan do-
main), the stop codon, and the 39-untranslated region with the poly-
adenylation signal sequence (ACAAAA) at 14 bp upstream from
the poly(A) tail.
Through the same bioinformatic tools used to identify s5d-srcrb,
a homologous gene mapping to an orthologous region of human
chromosome 19 was also identified. It corresponds to a recently
reported human gene (SSc5D), for which no biochemical and
functional data are available (22). Multiple alignments of the
amino acid sequences of the SRCR domains from the human and
mouse genes show a high degree (∼60%) of interdomain, as well
as interspecies amino acid identity (Fig. 1C). This indicates that
the five SRCR domains may have arisen from exon duplication.
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Expression of rmS5D-SRCRB-HA and generation of an S5D-
SRCRB–specific rat mAb
The full-length cDNA sequence of mouse s5d-srcrb was fused
in frame with a C-terminal HA tag and then cloned into the pCEP-
Pu vector for further expression into HEK 293-EBNA cells. Se-
rum-free supernatants from stable transfectants expressing this
rmS5D-SRCRB-HA protein were precipitated using TCA, sep-
arated on SDS-PAGE under reducing conditions, and subjected
to Western blot with an anti-HA mAb. This analysis rendered a
single broad band of ∼200 kDa in size (Fig. 2A), which is far great-
er than the predicted Mr (144.6 kDa) for the s5d-srcrb gene pro-
duct. The difference between the observed and expectedMr argues
in favor of rmS5D-SRCRB-HA undergoing posttranslational mod-
ifications. This was further confirmed by simultaneous Western
blot analysis of cell solubilizates and culture supernatants from
HEK 293-EBNA transfectants expressing rmS5D-SRCRB-HA.
As seen in Fig. 2C, the intracellular form of rmS5D-SRCRB-
HA was shown to display a smaller Mr (∼150 kDa) than did the
extracellular one (.200 kDa).
The rmS5D-SRCRB-HA present in serum-free supernatants
from stable transfectants was used as immunogen to generate spe-
cific rat mAbs. After several cloning and subcloning steps, seven rat
hybridomas were selected (Supplemental Table II). Their speci-
ficity was initially analyzed using ELISA plates precoated with
serum-free rmS5D-SRCRB-HA–containing supernatants. None of
the selected hybridomas was reactive to other HA-tagged group
B SRCR-SF members’ protein, such as S4D-SRCRB (24). The
same results were obtained following immunoprecipitation and
Western blot analyses of rmS5D-SRCRB-HA supernatant sam-
ples, further indicating that all rat mAbs generated recognized
rmS5D-SRCRB-HA under native (ELISA, immunoprecipitation)
and denaturing (Western blot) conditions; this suggests that the
mAbs are likely recognizing lineal epitopes.
Glycosylation studies
Because the predicted amino acid sequence of mouse S5D-SRCRB
contains multiple N-and O-linked glycosylation sites, the possi-
bility that glycosylation could account for the above-mentioned
posttranslational modifications was assessed. rmS5D-SRCRB-HA
was immunoprecipitated and then subjected to incubation with
different glycosidases, either alone or in combination. As illus-
trated in Fig. 2B, little or no change in Mr was observed when
rmS5D-SRCRB-HA was incubated with galactosidase, which re-
leases only b(1→4) terminal galactose residues. Partial sensitivity
could be observed toN-acetylglucosaminidase (Fig. 2B) and PNGase
F (data not shown), as deduced from the generation of a faint band
∼150 kDa, which is the predicted Mr for the unprocessed in-
tracellular form of S5D-SRCRB. Because N-acetylglucosamini-
dase cleaves all terminal b-linked N-acetylglucosamine residues
typical of N-linked glycosylations, and PNGase F cleaves all types
of Asn-linked sugars, some degree of N-glycosylation can be
inferred for S5D-SRCRB, which is in agreement with the presence
of putative N-glycosylation sites. Combined digestion with neur-
aminidase and O-glycosidase induced a small reduction in the
observedMr of rmS5D-SRCRB-HA (Fig. 2B), which was similar to
that observed for neuraminidase or O-glycosidase alone (data not
shown). This indicates that S5D-SRCRB also undergoes some
degree of O-glycosylation, as predicted from its relatively high
content of PST-rich sequences. In parallel experiments, all of the
glycosidases gave optimal digestion results when bovine fetuin was
used as a control glycoprotein (data not shown). These results in-
dicated that, although likely glycosylated, rmS5D-SRCRB-HA is
also relatively resistant to glycosidase treatment, as has often been
reported for some heavily glycosylated high Mr proteins (25, 26).
Tissue-expression analysis of s5d-srcrb
The expression pattern of S5D-SRCRB in normal mouse tissues
was assessed by immunohistochemistry (IHC) and RT-qPCR as-
says. Of the seven rat hybridomas generated, two (4D11.A2.H4
and 1H11.A8.G2) were shown to be appropriate for IHC studies on
paraffin-embedded tissues. The two mAbs gave identical staining
results with different retrieval methods (pepsin or target retrieval
solution). As illustrated in Fig. 3A, positive immunostaining was
detected throughout the gastrointestinal and genitourinary tracts.
Strong staining of serosal salivary gland and the exocrine part of
pancreas, as well as of testis, was observed. In kidney, selective
FIGURE 1. Gene and protein domain organization of mouse s5d-srcrb. A, The exon–intron organization of mouse s5d-srcrb and its correlation with the
domain organization of the predicted cDNA. B, Location of putative O-glycosylation sites along the protein sequence, according to the NetOGlyc 3.1
software. C, Alignment of amino acid sequences of SRCR domains from the predicted mouse and human S5D-SRCRB proteins. Conserved cysteine
residues are shown in black boxes. The gray boxes correspond to regions with .80% amino acid conservation.
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staining of a few tubular structures (likely corresponding to the
distal part of the collecting tubules) was observed. Lung and heart
gave negative staining results. A few scattered positive cells were
detected in spleen sections.
The RT-qPCR analysis of s5d-srcrb expression in normal mouse
tissues was in agreement with the above-mentioned IHC results.
Following normalization of gene expression to ribosomal 18S, the
greatest relative expression levels were observed in testis, kidney,
and pancreas. Low or negative relative expression was detected in
the rest of the analyzed tissues (Fig. 3B). Similar negative results
were observed when bone marrow-derived monocytes (resting or
LPS stimulated), and different cell lines of monocytic (Raw 264.7,
B10R), lymphocytic (EL-4, X63), or epithelial (266.6) origin were
analyzed (Supplemental Fig. 2). Taken together, these results il-
lustrate the restricted cell- and tissue-expression pattern of s5d-
srcrb.
The information obtained from tissue-expression assays was
used to validate the specificity of the anti–S5D-SRCRB rat mAbs
generated. Western blot analysis of RIPA solubilizates showed
mAb-reactive bands in testis but not in heart tissue, used as neg-
ative control (Fig. 2C). Similar negative results were obtained in
kidney and pancreas (data not shown), likely due to the low and
restricted expression observed in kidney and the relatively high
abundance of proteolytic enzymes present in exocrine pancreas.
Interestingly, the higher Mr bands observed in testis had a similar
Mr to those detected intra- and extracellularly in the transfectants
expressing rmS5D-SRCRB-HA, used as positive control. A band
of lower Mr (∼80 kDa) was also repeatedly observed in testis,
likely representing an alternatively spliced isoform or a partially
degraded form. Several attempts to immunoprecipitate S5D-
SRCRB from testis and other positive tissues (pancreas, kidney)
were unsuccessful. This indicated that the epitopes recognized by
the anti–S5D-SRCRB mAbs are inaccessible in the endogenous
protein under the solubilization conditions used (RIPA buffer) or,
more likely, that the mAbs do not bind properly in the stringent
solubilization buffer conditions used during RIPA-immunopre-
cipitation.
We also set out to study whether the expression of mouse S5D-
SRCRB is regulated during embryo development. Preliminary in
situ RNA-hybridization analysis carried out at day 9.5 postcoitum
showed that S5D-SRCRB is selectively detected in placodes,
embryonic ectodermal thickenings where organs or structures will
develop (Supplemental Fig. 3). RT-qPCR experiments also showed
a substantial increase in S5D-SRCRB RNA expression from days
9–14 postcoitum (Supplemental Fig. 4). These data suggested that
the expression of S5D-SRCRB is developmentally regulated.
Pathogen-binding and aggregating properties of recombinant
S5D-SRCRB
Given that some members of the SRCR-SF act as receptors for
PAMPs, the microbial-binding properties of rmS5D-SRCRB-HA
were assessed in vitro. Bacterial or fungal cell suspensions were
incubated with serum-free rmS5D-SRCRB-HA–containing super-
natants, and the presence of cell-bound protein was tested by West-
ern blot. As shown in Fig. 4A (left panel), rmS5D-SRCRB-HA
could be detected in cell pellets from most bacterial strains
assayed, either Gram-negative (E. coli, Salmonella typhimurium,
Yersinia enterocolitica, Shigella flexneri) or Gram-positive (S.
aureus, Staphylococcus epidermidis). Relatively low binding sig-
nal was observed for A. baumannii. In parallel assays, rmS5D-
SRCRB-HA also bound to all of the fungal strains analyzed, either
saprophytic (S. cerevisiae, S. pombe) or pathogenic (C. albicans,
Cryptococcus neoformans, A. fumigatus) (Fig. 4A, right panel). In
all cases tested, the binding of rmS5D-SRCRB-HA was dose de-
pendent (Fig. 4B). In full agreement with its pathogen-binding
properties, rmS5D-SRCRB-HA was also able to induce bacterial
and fungal aggregation, an effective mechanism to avoid dis-
semination of pathogenic agents and, thus, to control infection. As
shown in Fig. 5, addition of rmS5D-SRCRB-HA, but not BSA, to
microbial suspensions induced aggregation of Gram-positive (S.
aureus) and Gram-negative (E. coli, A. baumannii) bacteria, as
well as fungi (C. albicans).
PAMP recognition by S5D-SRCRB
The nature of the cell wall component(s) responsible for the
bacterial- and fungal-binding ability of mouse S5D-SRCRB was
studied by ELISA. Plastic plates were coated with different PAMPs
(PGN, LPS, LTA, zymosan, glucan, mannan) and then incubated
with serum-free rmS5D-SRCRB-HA supernatants. The presence of
bound mS5D-SRCRB-HAwas developed using anti–S5D-SRCRB
rat mAb plus HRP-conjugated anti-rat IgG antiserum. As shown
in Fig. 6, significant dose-dependent binding of rmS5D-SRCRB-
HA could be detected to PGN, LPS, zymosan, and linear b-glucan
but not to LTA, mannan, or branched b-glucans.
Binding of testis S5D-SRCRB proteins to microbial surfaces
Next, we also studied whether the endogenous mouse S5D-SRCRB
protein form(s) expressed in testis also retain(s) the microbial-
binding properties of the recombinant protein (rmS5D-SRCRB-
HA). S. aureus was chosen for these studies because our results
showed that it gave the best binding. Thus, bacterial cell sus-
FIGURE 2. Analysis of recombinant and tissue-expressed mouse S5D-
SRCRB. A, Expression of rmS5D-SRCRB-HA by human HEK 293-EBNA
cells. Samples of TCA-precipitated serum-free culture supernatants from
transfected (+) and untransfected (2) cells were run on 7.5% SDS-PAGE
under reducing conditions and transferred to nitrocellulose for Western
blot analysis with an anti-HA mAb plus HRP-conjugated anti-mouse IgG
antiserum. B, Glycosylation analysis of rmS5D-SRCRB-HA. Serum-free
culture supernatants from HEK 293-EBNA transfectants expressing
rmS5D-SRCRB-HA were immunoprecipitated with 1H11.A8.G2 mAb.
The immune complexes were then incubated for 3 h at 37˚C with the in-
dicated glycosidases, alone (galactosidase, N-acetylglucosaminidase) or in
combination (neuraminidase plus O-glycosidase [Nase+O-Gly]). The
resulting products were analyzed by Western blot using a 1:2 dilution of rat
1H11.A8.G2 hybridoma supernatant plus goat HRP-conjugated goat anti-
rat IgG. C, Comparative Western blot analysis of recombinant and tissue-
expressed mouse S5D-SRCRB. Samples of serum-free culture super-
natants (extracel.) and detergent (1% Nonidet P-40) cell solubilizates
(intracel.) from stable HEK 293-EBNA transfectants were analyzed in
parallel with soluble fractions of RIPA homogenates from mouse heart and
testis. Samples were run on 7.5% SDS-PAGE under reducing conditions
and transferred to nitrocellulose for Western blot analysis, as in B.
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pensions were incubated with liver and testis tissue solubilizates
and then pelleted, extensively washed, and resolved by SDS-PAGE
under reducing conditions for further Western blot analysis. As
shown in Fig. 4C, anti–S5D-SRCRB–reactive bands were re-
covered in S. aureus cell pellets adsorbed onto testis but not liver
homogenates. The observed bands corresponded to the greatest
(fully processed) and smallest (alternatively spliced or proteoliti-
cally processed) Mr forms of mouse S5D-SRCRB (Fig. 2C). No
evidence of reactivity with the intermediate Mr (intracellular, in-
completely processed) form was observed.
Inhibition of PAMP-induced cytokine release by S5D-SRCRB
Our results showed that rmS5D-SRCRB-HA bound to bacteria and
was able to induce aggregation. We next studied whether rmS5D-
SRCRB-HA has intrinsic bactericidal activity. As shown in Sup-
plemental Fig. 5, our preliminary results suggested that rmS5D-
SRCRB-HA does not display measurable bactericidal activity at
a concentration of 1 mg/ml. Similar results were obtained with
rmS5D-SRCRB-HA concentrations #20 mg/ml (data not shown).
We then sought to determine whether the interaction of S5D-
SRCRB with PAMP could affect a biological outcome, such as
cytokine release. HEK 293 cells stably transfected with TLR2
release IL-8 when exposed to PGN, a known PAMP and TLR2
ligand. We then exposed these cells, as well as untransfected HEK
293 cells, to PGN in the presence or absence of rmS5D-SRCRB-
HA–containing supernatant. As shown in Fig. 7, release of IL-8
induced by PGN was dose-dependently inhibited by rmS5D-
SRCRB-HA; inhibition was significant (p , 0.05) when 100 ml
supernatant was used. Supernatant from untransfected HEK 293
cells did not affect IL-8 release by HEK 293 TLR2 cells (data not
shown).
Binding of mouse S5D-SRCRB endogenous extracellular
proteins
Archetypical members of the SRCR-SF (e.g., DMBT1/gp340/
SAG) were reported to interact with exogenous pathogens, as
well as with endogenous host components (27). Therefore, it was
tested whether this could also be the case for S5D-SRCRB. First,
we explored its binding to different purified extracellular matrix
proteins by ELISA. As illustrated by the results presented in Fig.
8A, rmS5D-SRCRB-HA showed clear dose-dependent binding
to laminin. Low (fibronectin) or negative (collagen I and IV) bind-
ing was observed for other extracellular matrix components. An-
other set of experiments demonstrated the sugar-dependent inter-
action of S5D-SRCRB with galectin-1, a broadly expressed homo-
dimeric mammalian lectin secreted by epithelial cells (28). As
shown in Fig. 8B, specific binding of rmS5D-SRCRB-HA to
GST-Gal1 Sepharose beads was competed in a dose-dependent
FIGURE 3. Tissue-expression analysis of mouse
S5D-SRCRB. A, Immunohistochemical staining of
paraffin-embedded mouse tissue sections (kidney, du-
odenum, stomach, testis, pancreas, salivary gland,
lung, spleen, and heart) with rat 4D11.A2.H4 mAb
(1:10 dilution). Development was carried out with
HRP-conjugated anti-rat IgG and nuclear counter-
staining in Mayer’s hematoxylin (original magnifica-
tion 310). B, RT-qPCR analysis of mouse S5D-
SRCRB tissue expression. RNA preparations from
TRIzol-treated C57BL/6J adult mouse tissue were used
as a template for cDNA synthesis with the GeneAmp
PCR kit. Further amplification of 18S and s5d-srcrb
genes was performed as described in Materials and
Methods. Relative gene copy number was normalized
to housekeeping 18S and expressed as arbitrary units
with error bars from duplicates. A representative ex-
periment of three performed is shown.
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(3–30 mM) manner by lactose but not by another irrelevant sugar
(sucrose). Taken together, the results indicated that, once secreted,
S5D-SRCRB could be immobilized to relevant constituents of the
extracellular milieu (e.g., laminin and galectin-1, and perhaps
other unidentified proteins as well), thus putatively contributing to
basic homeostatic epithelial cell functions.
Discussion
Epithelial cells form physical barriers that are covered by muco-
sal surfaces aimed at preventing the entry of invading pathogens.
Moreover, spontaneously or following the sensing of microbial
components, epithelial cells can also synthesize effector molecules
that trigger or increase the defensive immune responses of the host
(i.e., mucosal inflammation and other related innate and adaptive
immune responses) (29–33). The present work reports the iden-
tification and further molecular and functional characterization of
a new mouse receptor (S5D-SRCRB) mainly expressed by some
epithelial cell types and likely belonging to the humoral arm of the
innate immune system. This receptor possesses the characteristics
of group B members of the SRCR-SF (3, 5), and it should be
considered the mouse homolog of SSc5D (22). A relevant finding
of the current study is the demonstration that mouse S5D-SRCRB
behaves as a PRR. Thus, S5D-SRCRB should be added to the
short, although still-growing, list of members of the SRCR-SF
showing pathogen-binding properties. This ability has been un-
equivocally mapped to the SRCR itself in only a few members,
including MARCO, CD163, DMBT1/SAG/gp340, CD5, CD6, and
FIGURE 4. Binding of mouse S5D-SRCRB to microbial organisms. A,
Direct binding assays of rmS5D-SRCRB-HA to bacterial and fungal
strains. Samples (250 ml) of serum-free supernatants from stable trans-
fectants expressing rmS5D-SRCRB-HAwere incubated for 1 h at 4˚C with
the indicated bacterial (5 3 107) or fungal (5 3 106) cell suspensions in
binding buffer (TBS, 1% BSA, 5 mM CaCl2). Cell pellets were washed
thoroughly and then resuspended in Laemmli’s sample buffer for further
separation in 6% SDS-PAGE. Cell-bound protein was subsequently
detected by Western blot analysis, as described in Materials and Methods.
B, Dose-dependent binding of rmS5D-SRCRB-HA to bacterial and fungal
strains. Increasing amounts of serum-free supernatants from stable trans-
fectants expressing rmS5D-SRCRB-HA were incubated with 5 3 107
Gram-positive (S. aureus) and Gram-negative (E. coli) bacteria, as well as
with 5 3 106 pathogenic (C. albicans) and saprophytic (S. cerevisiae)
fungi. Bound protein was recovered and detected as described above. C,
Binding of bacteria to tissue-expressed mouse S5D-SRCRB. Mouse testis
and liver tissue was homogenized in three volumes of binding buffer (see
above), and 100 ml of their soluble fractions was incubated for 1 h at 4˚C
with 5 3 107 S. aureus. Presence of cell-bound mouse S5D-SRCRB
protein was analyzed by Western blot, as in A.
FIGURE 5. Aggregation of bacterial and fungal cell suspensions by
mouse S5D-SRCRB. The indicated strains of bacteria and fungi were la-
beled with FITC and incubated overnight at room temperature with 20 mg/
ml of affinity-purified rmS5D-SRCRB-HA or BSA, used as negative
control. After extensive washing, the cells were observed by fluorescence
microscopy. Original magnification 3100.
FIGURE 6. Binding of mouse S5D-SRCRB to conserved microbial cell
wall components. A, Binding of rmS5D-SRCRB-HA to bacterial cell wall
components. ELISA plates were coated overnight at 4˚C with 2 mg/well of
LPS, PGN, or LTA. After blocking with PBS 3% BSA, 2-fold serial
dilutions of serum-free supernatants (100 ml) from transfectants expressing
HA-tagged mouse S5D-SRCRB were added to wells and incubated for 2 h
at room temperature. Bound protein was detected using 1H11.A8.G2 mAb
plus HRP-conjugated goat anti-rat IgG antiserum. Plates were developed
with TMB substrate solution, and additional absorbance was measured at
450 nm. B, Binding of rmS5D-SRCRB-HA to fungal cell wall compo-
nents. ELISA plates were coated overnight at 4˚C with 2 mg/well of zy-
mosan, b-glucans (linear or branched), and mannan. After blocking, well
plates were incubated for 2 h at room temperature with 100 ml samples of
2-fold serial diluted serum-free supernatants from transfectants expressing
rmS5D-SRCRB-HA. Bound protein was detected as in A. The assays
shown in A and B were repeated twice with similar results.
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Spa. In some instances, the amino acid sequence motifs involved
in SRCR-mediated pathogen recognition have been precisely
identified (RxR, VEVLxxxxW) (15, 16, 20), but an exact match to
these motifs is not observed among any of the SRCR domains of
S5D-SRCRB. However, by no means does this exclude the SRCR
domains of mouse S5D-SRCRB as being responsible for pathogen
recognition, as exemplified by Spa, CD6, and CD5 (17–19). The
SRCR domains are among the few protein modules from which
evolution has settled a myriad of structurally related but func-
tionally different proteins. Key residues that stabilize the core
structure of SRCR domains are well conserved, whereas amino
acid positions at externally oriented connecting loops are keen to
change, thus generating protein versatility. This versatility may
have given rise to a certain degree of functional diversity among
the members of the SRCR-SF that would justify the lack of
a unifying function for all SRCR-SF members; this is exemplified
even when exploring the pathogen-binding properties of SRCR-SF
members. However, mutational investigations to exclude the pos-
sibility that the non-SRCR domains of S5D-SRCRB could ac-
count for its pathogen-binding properties remain to be performed.
Intriguingly, mouse S5D-SRCRB presents several structural and
functional analogies with the human secreted protein DMBT1, also
known as gp340 or salivary agglutinin (SAG), and which also
corresponds to rat ebnerin, mouse Crp-ductin, or rabbit hensin (5).
DMBT1/gp340/SAG is an archetypal group B SRCR-SF protein
involved in infection, inflammation, and cancer (34). From a
structural point of view, it is a mosaic-type glycoprotein composed
of 14 SRCR domains interspersed by PST-rich sequences and
possessing two C1r/C1s Uegf Bmp1 and one zona pellucida
domains at its C-terminal region. Functionally, DMBT1/gp340/
SAG represents an innate defense factor interacting with a broad
spectrum of pathogens (bacteria, fungi, viruses), as well as mu-
cosal defense proteins (galectins, IgA, surfactant A and D pro-
teins, MUC5B, TFF2). In contrast, it drives epithelial and stem
cell differentiation as an extracellular matrix protein, whereas
inactivation of its gene is associated with tumor formation (34).
Mouse S5D-SRCRB should also be considered a mosaic protein
because it is composed of five SRCR domains interspersed by
PST-rich sequences and possessing a C-terminal syndecan-like
domain. Syndecans are heparan sulfate proteoglycans that are
known to mediate interactions with extracellular matrix proteins
and heparin-binding growth factors. Preliminary data support the
putative interaction of rmS5D-SRCRB-HA with some extracellu-
lar matrix proteins, such as laminin and, to a lesser extent, fi-
bronectin, but not collagen I or IV. Moreover, we also provide
evidence on the carbohydrate-dependent interaction of mS5D-
SRCRB-HA with galectin-1, a host soluble lectin that functions
as a damage-associated molecular pattern and a receptor for
PAMPs (35). The mucosal-defense properties of mouse S5D-
SRCRB against living organisms are supported by its broad
binding and aggregating microbial spectrum that includes sapro-
phytic and pathogenic bacteria and fungi; potential interactions
with viruses remain to be studied. Our preliminary data indicated
that this defensive role is played in the absence of detectable in-
trinsic bactericidal activity, which is not unusual for innate-
immunity proteins; SAG is a well-known example of a non-
bactericidal protein with defensive properties. By binding to mi-
crobial components, mouse S5D-SRCR seems to downregulate
subsequent PAMP-induced cytokine release, as deduced from our
experiments showing dose-dependent inhibition of IL-8 release
following PGN stimulation of HEK 293 TLR2 transfectants. We
consider that this could be important for preserving the integrity
and the function of epithelia from excessive or prolonged in-
flammation caused by PAMPs in those tissues where S5D-SRCRB
is expressed. This is best exemplified by the expression of mouse
S5D-SRCRB in seminiferous testicular tubules, where infection
and inflammation may cause male infertility, thus compromising
murine reproductive capability (36). The expression of mouse
S5D-SRCRB in these tissues also argues in favor of its putative
FIGURE 7. Downmodulation of PGN-induced IL-8 release by mouse
S5D-SRCRB. HEK 293 cells that were untransfected or stably expressing
TLR2 were seeded on a 96-well plate at a density of 53 104 cells per well,
grown for 24 h, and then cultured in serum-free media for an additional 24
h. Cells were then pulsed with 20 mg/ml PGN for 24 h in the presence of
supernatants from HEK 293-EBNA transfectants expressing rmS5D-
SRCRB-HA or serum-free media as negative control. IL-8 was then
assayed in culture supernatant samples by ELISA. Results represent the
average of four independent experiments. *p , 0.05.
FIGURE 8. Interaction of rmS5D-SRCRB-HA with endogenous extra-
cellular proteins. A, Binding of S5D-SRCRB to extracellular matrix pro-
teins. Serial 2-fold dilutions of serum-free rmS5D-SRCRB-HA
supernatants were added to 96-well ELISA plates coated with the indicated
purified extracellular matrix proteins and left overnight at 4˚C. Bound
rmS5D-SRCRB-HA was detected using the 4D11.A2.H4 hybridoma su-
pernatant plus a goat anti-rat IgG/HRP antiserum (Sigma). Plates were
developed by adding TMB substrate (Sigma), and the absorbance was
measured at 450 nm. The assay was repeated twice with similar results.
FN, fibronectin; LM, laminin; C I, collagen I; C IV, collagen IV. B, Sugar-
dependent binding of S5D-SRCRB to galectin-1. GST-Gal1 Sepharose
beads (GST-Gal1) were incubated overnight at 4˚C with a fixed amount (25
ml) of serum-free rmS5D-SRCRB-HA supernatants (total protein) in the
presence or absence of increasing concentrations (3, 15, and 30 mM) of
competing (lactose) or noncompeting (sucrose) sugars. Bound proteins
were eluted with Laemmli’s sample buffer and separated on 6% SDS-
PAGE under reducing conditions for further Western blot analysis with
1H11.A8.G2 mAb plus HRP-labeled anti-rat IgG. Chemiluminescence
results are presented.
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role in cell-differentiation processes. Interestingly, preliminary
data from our group indicate that expression of mouse S5D-
SRCRB is regulated during embryo development. More pre-
cisely, in situ RNA hybridization results at day 9.5 postcoitum
showed that S5D-SRCRB is selectively detected in placodes,
embryonic ectodermal thickenings where organs or structures
will develop (37). Moreover, RT-qPCR data indicate that there is
an important relative increase in its RNA expression from days 9–
14 postcoitum, the meaning of which remains to be explored
further. Finally, the relative preferential expression of mouse S5D-
SRCRB observed in adult testis also opens the possibility that it
may behave as a nonchromosome X-encoded cancer/testis Ag
(38). Therefore, a systematic investigation of mouse S5D-SRCRB
expression in human and mouse tumors should be performed to
exclude this possibility.
The very limited information available on human SSc5D high-
lights the need for future studies to explore whether the function-
al and structural characteristics reported in this article for mouse
S5D-SRCRB also apply to its human homolog. At present, marked
differences exist regarding their tissue-expression pattern. Al-
though the highest expression level of SSc5D is reported in pla-
centa, spleen, colon, and lung, mouse S5D-SRCRB is mainly
expressed in testis, kidney, and the serosal region of salivary and
pancreas glands. To further clarify this point, parallel IHC analyses
of mouse and human tissues performed with the 1H11.A8.G2 mAb,
which shows human–mouse species cross-reactivity (U. Holm-
skov, unpublished observations), are urgently needed. The dem-
onstration of conserved binding capabilities to a broad spectrum
of pathogens, as well as to endogenous proteins, by the human
protein homolog also requires further investigation.
In summary, to our knowledge, the molecular and functional
characteristics of a new mouse group B SRCR-SF member, S5D-
SRCRB, have been reported in this article for the first time. Apart
from its likely involvement in protection against pathogenic or
saprophytic microorganisms of the restricted epithelial surfaces
where mouse S5D-SRCRB is expressed, other functions related
to epithelial cell differentiation and homeostasis should be taken
into consideration in future studies.
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SUPPLEMENTARY INFORMATION 
 
Supplementary FIGURE 1. Nucleotide sequence and deduced amino acid sequence of 
mouse s5d-srcrb. The putative signal peptide is double underlined. SRCR domains are 
single underlined and the sequence with homology to syndecan domain is dash 
underlined. Nucleotides at the exon-intron boundaries are highlighted in bold italics. 
The putative N-glycosylation sites and the stop codon are marked with a circle and an 
asterisk, respectively. 
 
Supplementary FIGURE 2. RT-qPCR analysis of s5d-srcrb expression in normal and 
leukemic cells. TRIzol total RNA preparations from the indicated mouse cells and 
tissues were retrotranscribed into cDNA using the SuperScriptTM III First-Strand 
Synthesis System (Invitrogen). The primers and cycling conditions used for 
amplification of 18S and s5d-srcrb genes were the same as those used in Fig. 3 and 
reported in the Materials and Methods section. Gene expression was normalized to 
housekeeping gene 18S and expressed in arbitrary units. BMDMo resting, unstimulated 
bone marrow-derived monocytes (>95% CD11+); BMDMo LPS(+), BMDMo activated 
for 6 hs with 1ng/ml LPS. HEK 293 transfectants, HEK 293-EBNA cells stably 
expressing rmS5D-SRCRB-HA.  
 
Supplementary FIGURE 3. Developmental expression of the s5d-srcrb transcript. 
Mouse embryos were obtained from CD1 mice matings and collected at 9.5 dpc. 
Whole-mount in situ hybridization was performed essentially as described*, using 
digoxigenin-labelled riboprobes. Digoxigenin was detected with NBT/BCIP (Roche) 
which gives a purple staining. After staining, embryos were fixed in 4% PFA, 
cryoprotected in 15% sucrose and embedded in 7.5% gelatine/15% sucrose. Blocks 
were frozen in 2-Methylbutane (Sigma) to improve tissue preservation, then sectioned 
at 20 μm thickness on a Leica CM 1510-1 cryostat. Whole mount embryos and sections 
were imaged under a fluorescence microscope Leica DM6000B. Whole-mount in situ 
hybridization of 9.5 dpc embryos with s5d-srcrb antisense (a-d) and sense (e-h) probe. 
To generate both probes, cDNA was synthesized from total RNA amplified using 
primers msd1.FW and msd2.Rv cDNA was then cloned in a pFLCI vector (Qiagen). To 
obtain the antisense probe, the plasmid was linearized with SalI (Roche) and transcribed 
with T3-RNApolimerase (Roche). Similarly, for the sense probe linearization was 
carried out with SstI (Roche) and transcription was performed with T7-RNApolimerase. 
Note that specific RNA staining with antisense probe revealed s5d-srcrb expression in 
the anterior and lateral aspects of the otic vesicle and in the olfactory placode. nt, neural 
tube; ov, otic vesicle; olp, olfactory placode. 
* Wilkinson, D.G., Nieto, M.A., 1993. Detection of Messenger-Rna by in-Situ 
Hybridization to Tissue-Sections and Whole Mounts. In Guide to Techniques in Mouse 
Development. 225. p. 361-373. 
 
Supplementary FIGURE 4. RT-qPCR analysis of s5d-srcrb expression at embryo 
developmental stages. RNA preparations were obtained from eight different embryos of 
C57BL/6J mouse at 9 dpc (a, b, c and d) and 14 dpc (A, B, C and D) using TRIzol 
(Invitrogen). cDNA synthesis was carried out using the GeneAmp PCR kit (Roche). 
The primers and cycling conditions used for amplification of 18S and s5d-srcrb genes 
were the same as those used in Fig. 3 and reported in the Material and Methods section. 
Gene expression was normalized to housekeeping gene 18S and expressed in arbitrary 
units. 
 
Supplementary FIGURE 5. Bactericidal activity was determined by a modification of 
the turbidimetric growth assay described by Muschel and Treffers (38). S. aureus at 
5x106 CFU/ml in TBS plus 5 mM CaCl2 were grown alone or exposed to purified 
rmS5D-SRCRB-HA or BSA for 45 min in a shaker at 37°C and 280 rpm. After this 
time, the culture was inoculated into 5 ml LB and further incubated at 37°C and 280 
rpm until turbidity measured at 600 nm in control tubes reached a DO of between 0.5 
and 0.6. Serial dilutions of the cultures were then performed and plated in LB agar and 
the number of colonies counted in duplicate after overnight incubation at 37ºC. Two 
independent experiments were performed, with similar results; a representative out of 
the two is shown here. 
 
ctggtctcaggtccccacggatgtgccggccgcctggaagtctggcacggtggacgttggggcactgtctgtgatgatggatgggacctccgagatgcagcggtggcctgcagggagctg
gctagctgtccagggctcctcagcagctgcttccctccctggctgcctcctcctcccctctcctgccctccttcccctttcaccccatcccctgcccctggactctgcgaac
atgaggggcttggcctgcctcctt gcaatgctggtggggatccaggctata gagcgactccgcctggctgatggtcctcatggctgcgcaggacgcctggaggtctggcacagcgggcgc
M  R  G  L  A  C  L  L  A  M  L  V  G  I  Q  A  I  E  R  L  R  L  A  D  G  P  H  G  C  A  G  R  L  E  V  W  H  S  G  R
tggggcaccgtgtgtgatgacggatgggaccttcgggatgctgaagtggcctgccgtgtgttaggctgcggaggggcgctggcagcccctgggggtgccttcttcggggagggcactggg
W  G  T  V  C  D  D  G  W  D  L  R  D  A  E  V  A  C  R  V  L  G  C  G  G  A  L  A  A  P  G  G  A  F  F  G  E  G  T  G
cctgtatggctcagtgaactgaactgtcggggcaatgagggtcagctgggtatctgtccccaccggggctggaaggcccatatctgctctcatgaggaggacgcaggcgtcgtctgtgta
P  V  W  L  S  E  L  N  C  R  G  N  E  G  Q  L  G  I  C  P  H  R  G  W  K  A  H  I  C  S  H  E  E  D  A  G  V  V  C  V
ggtcagcgtgcagctaactctagagaagattcaatgtccctgctggatggggatccatggctggcactgtctggggagctaagccccagctcagaggagccccctataactcac gctccc
G  Q  R  A  A  N  S  R  E  D  S  M  S  L  L  D  G  D  P  W  L  A  L  S  G  E  L  S  P  S  S  E  E  P  P  I  T  H  A  P
caaccagcagcaagctcccagaatggcccccggaagaagaacccccggccacccaagcagaccaagtccacccgagcccctgtactgacaaatggagctccccaccaa gagcggctgcga
Q  P  A  A  S  S  Q  N  G  P  R  K  K  N  P  R  P  P  K  Q  T  K  S  T  R  A  P  V  L  T  N  G  A  P  H  Q  E  R  L  R
L  V  S  G  P  H  G  C  A  G  R  L  E  V  W  H  G  G  R  W  G  T  V  C  D  D  G  W  D  L  R  D  A  A  V  A  C  R  E  L
ggatgtgggggagcgctggccgcccctgggggtgccagatttggacctggtgagggacctgtgtggatggatgacgtggggtgtggaggaggagaggaggccctccgagactgtccccga
G  C  G  G  A  L  A  A  P  G  G  A  R  F  G  P  G  E  G  P  V  W  M  D  D  V  G  C  G  G  G  E  E  A  L  R  D  C  P  R
agcccctggggccggagcaactgtgaccacaccgaggatgcagggctggtctgcacc ggtcctgcacccaggatacgccttgctgatggtccccacggctgtgctggccgcctggaggtg
S  P  W  G  R  S  N  C  D  H  T  E  D  A  G  L  V  C  T  G  P  A  P  R  I  R  L  A  D  G  P  H  G  C  A  G  R  L  E  V
tggcatggtggacgatgggggtcggtgtgtgacgatgcctgggatcttcgcgatgctgctgtggcctgcaaggagctgggctgtgggggtgccctggccgccccagggggcgccttcttt
W  H  G  G  R  W  G  S  V  C  D  D  A  W  D  L  R  D  A  A  V  A  C  K  E  L  G  C  G  G  A  L  A  A  P  G  G  A  F  F
ggagaggggactggacccatcatcctggatgatctcagatgtcgaggaaatgagacagccttgcgattctgtcctgcgaggccctggggtcagcacgactgtcaccaccgggaggatgct
G  E  G  T  G  P  I  I  L  D  D  L  R  C  R  G  N  E  T  A  L  R  F  C  P  A  R  P  W  G  Q  H  D  C  H  H  R  E  D  A
ggggccgtgtgtgat ggcatgcctctcggtgctgtgcagcctacagttcctgcagtggacagcaacagcacagcacacaggcttctgtctacctccgtgggtcagatgccaggcccagca
G  A  V  C  D  G  M  P  L  G  A  V  Q  P  T  V  P  A  V  D  S  N  S  T  A  H  R  L  L  S  T  S  V  G  Q  M  P  G  P  A
ggcccttggcctccttctgcttctcctactgcccctccagagcctgggcccgaagct gggtccccccagttgcgcctggtggctggacccagcaggtgctctggccggctggaggtatgg
G  P  W  P  P  S  A  S  P  T  A  P  P  E  P  G  P  E  A  G  S  P  Q  L  R  L  V  A  G  P  S  R  C  S  G  R  L  E  V  W
catgacggacgctgggggacagtatgtgatgacagctgggacatgagagactcagctgtggtctgccgggagctgggctgtgggaggcctcggcaaccagaccccgcagcaggccgcttt
H  D  G  R  W  G  T  V  C  D  D  S  W  D  M  R  D  S  A  V  V  C  R  E  L  G  C  G  R  P  R  Q  P  D  P  A  A  G  R  F
ggctggggtgcaggccccatctggctggatgacgtaggttgtatggggacggaggcttcactgtcagaatgccctgctgcttcctgggggaaacacaattgcgcccacaatgaggatgtc
G  W  G  A  G  P  I  W  L  D  D  V  G  C  M  G  T  E  A  S  L  S  E  C  P  A  A  S  W  G  K  H  N  C  A  H  N  E  D  V
ggggttacctgcact gggacccccggcctggataccatctcagaccctttcagttggagctggctccctgggctgggtagagatcaggatgcctggctcccaggagagctaaccaccaaa
G  V  T  C  T  G  T  P  G  L  D  T  I  S  D  P  F  S  W  S  W  L  P  G  L  G  R  D  Q  D  A  W  L  P  G  E  L  T  T  K
ccttctgccagtctcacctccagtgtgccacagaaacccacaaaggttccagggaaagctcccaagagtaccaagaagtgggtgactaaaaatgcaaggagaccaaccactcagccccct
P  S  A  S  L  T  S  S  V  P  Q  K  P  T  K  V  P  G  K  A  P  K  S  T  K  K  W  V  T  K  N  A  R  R  P  T  T  Q  P  P
gggatgccaaccaccaaacattccagggccccaggcaccccaacctccctacatccaacagcacgtacctctgagttaccaaagagactgaccactgaggctccccacaggcagacctca
G  M  P  T  T  K  H  S  R  A  P  G  T  P  T  S  L  H  P  T  A  R  T  S  E  L  P  K  R  L  T  T  E  A  P  H  R  Q  T  S
cataccactgtaaggctgacccctagggtcccctgggagtggacctcagagcctgtggtgtcacagtccactcaaggtccccaagaagtgacctctgaggccaccacaacggaaaaccct
H  T  T  V  R  L  T  P  R  V  P  W  E  W  T  S  E  P  V  V  S  Q  S  T  Q  G  P  Q  E  V  T  S  E  A  T  T  T  E  N  P
cagacctctttggagccatcgggtgagaacaccgaaggctctctggaatcatcccaagatccagctaccaccccaactgctggagtccctgtgccatca ggtcccttccgggttcgtctg
Q  T  S  L  E  P  S  G  E  N  T  E  G  S  L  E  S  S  Q  D  P  A  T  T  P  T  A  G  V  P  V  P  S  G  P  F  R  V  R  L
gctgatgggcccaacaggtgtgctggccggctagaggtgtggcatgctggactctggggaacagtctgtgatgacagctgggacatccgggatgccacagtggcctgctgggagctgggt
A  D  G  P  N  R  C  A  G  R  L  E  V  W  H  A  G  L  W  G  T  V  C  D  D  S  W  D  I  R  D  A  T  V  A  C  W  E  L  G
tgcggaaaggtccggccccgagtaggcaaaactcactatggccctggcactgggcccatctggttggatgacatgggctgtaaaggaagtgagatgtcactgagtgactgcccctcgggg
C  G  K  V  R  P  R  V  G  K  T  H  Y  G  P  G  T  G  P  I  W  L  D  D  M  G  C  K  G  S  E  M  S  L  S  D  C  P  S  G
gcatgggggaagcacaactgtgaccacgaagaagacgtggtgctcacctgcact ggctacacgggtgatgacgattatccttcctggacctgggaccctacttccggagaggacctgacc
A  W  G  K  H  N  C  D  H  E  E  D  V  V  L  T  C  T  G  Y  T  G  D  D  D  Y  P  S  W  T  W  D  P  T  S  G  E  D  L  T
aaagggaccacagtggctgcgcggcctggacatacactttcctgggctaccactacaaacactgaagtcccctctccagcaacacagaaccttccagacacg gatgaccagggaggttat
K  G  T  T  V  A  A  R  P  G  H  T  L  S  W  A  T  T  T  N  T  E  V  P  S  P  A  T  Q  N  L  P  D  T  D  D  Q  G  G  Y
gagtcttcctggacgtgggatacaccttcaggaaggggtctgttcaaggggacccccaccacaaccaagcctggatccacagttaccactagcaccagcaagagtcccggccaccccttt
E  S  S  W  T  W  D  T  P  S  G  R  G  L  F  K  G  T  P  T  T  T  K  P  G  S  T  V  T  T  S  T  S  K  S  P  G  H  P  F
ccagctccaagggcccgtgca ggttcaccaaggaagccaacacctgagcgccggccgctgcccacctcagccaccacctcatctcctgcttcctcctcttcaccagagccttctggctca
P  A  P  R  A  R  A  G  S  P  R  K  P  T  P  E  R  R  P  L  P  T  S  A  T  T  S  S  P  A  S  S  S  S  P  E  P  S  G  S
cggcagacctctggctcctggccacaactcatcccagactcaaagcaggaggggacctctagctcccccaaaccatctctactcaccccaggacttccctccccagcaacctttgccttg
R  Q  T  S  G  S  W  P  Q  L  I  P  D  S  K  Q  E  G  T  S  S  S  P  K  P  S  L  L  T  P  G  L  P  S  P  A  T  F  A  L
tccactcctaataccagtttgcttccaacacgttccccagagctttcaggcagcccaacacccacctcccctgaagggctaacctctgcctcctctatgctatcagaagtgagcaggctt
S  T  P  N  T  S  L  L  P  T  R  S  P  E  L  S  G  S  P  T  P  T  S  P  E  G  L  T  S  A  S  S  M  L  S  E  V  S  R  L
tctcctacctcagagctgactccaggacctgatacaacaccagcacctgaaataatcccagaaagttctgactcctcagacctccccatgaacaccaggacccccacacagccgtttaca
S  P  T  S  E  L  T  P  G  P  D  T  T  P  A  P  E  I  I  P  E  S  S  D  S  S  D  L  P  M  N  T  R  T  P  T  Q  P  F  T
gcctctcaccccaccagcatccctcaactcaacacaacttcttaccccaccattgcccctcaacctaccacaaaccctcagcaacccaggagccctcaccccgccacaagtcctcaacct
A  S  H  P  T  S  I  P  Q  L  N  T  T  S  Y  P  T  I  A  P  Q  P  T  T  N  P  Q  Q  P  R  S  P  H  P  A  T  S  P  Q  P
cccaccaatactcacccttcctcaacccctgccacccctacagagtcccttccatcctcccgaaagacagaactttcctctcccactaagcctagactaaactcagagttgacctttgag
P  T  N  T  H  P  S  S  T  P  A  T  P  T  E  S  L  P  S  S  R  K  T  E  L  S  S  P  T  K  P  R  L  N  S  E  L  T  F  E
gaagccccatccacagacgcatcccagacgcagaacctagagctctttctagcctcggagtccggcccctccagtccctctccagcctcaaacttggacccactacccacagatgccttc
E  A  P  S  T  D  A  S  Q  T  Q  N  L  E  L  F  L  A  S  E  S  G  P  S  S  P  S  P  A  S  N  L  D  P  L  P  T  D  A  F
aaaccacccagaagccagaccttacactcagcttcagaccacctcactcaagggccaacccctaatcacaacccagatccttttgggccatgtgtgtccccattaccaccagtaagggtc
K  P  P  R  S  Q  T  L  H  S  A  S  D  H  L  T  Q  G  P  T  P  N  H  N  P  D  P  F  G  P  C  V  S  P  L  P  P  V  R  V
atggcttgtgagccacctgccttggtggagctggtaggtgctgtgagggaggtgggtgaccagctgcagagactgacctgggtcctggagcaggaccggcaggagcgccaagtcctggca
M  A  C  E  P  P  A  L  V  E  L  V  G  A  V  R  E  V  G  D  Q  L  Q  R  L  T  W  V  L  E  Q  D  R  Q  E  R  Q  V  L  A
ctgggcctagcccagttggtagaggctgctcaggggttggggcagctgagtgagactgtaaagaggctagcagaggtggcctggccccccagcactcctgtgcccatgaccaccaccaca
L  G  L  A  Q  L  V  E  A  A  Q  G  L  G  Q  L  S  E  T  V  K  R  L  A  E  V  A  W  P  P  S  T  P  V  P  M  T  T  T  T
gaggaggaggagaggcctctgaggggagatgtgtgacccactctgaaattcacggtgcttaagatactc
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Supplementary Table I. Source of EST clones with the highest E-value for s5d-srcrb. 
 
 
EST Tissue source  Size (nt) 
E value
 
gb BU704083.1 Whole brain: 12.5dpc 1355 0.0 
gb BU522633.1 Colon 1220 0.0 
gb AI430129.1 E13.5-14.5dpc total fetus 1142 0.0 
gb BU756713.1 Trophoblast 1040 0.0 
emb CR756934.1 muscle 1031 0.0 
gb BQ832084.1 Fetal liver 1027 0.0 
emb CR757678.1 Muscle 1023 0.0 
gb BQ287699.1 E10.5, E12.5, E16.5, newborn, adult, mixed 1014 0.0 
emb CR756931.1 Muscle 942 0.0 
gb BU056602.1 Whole brain of E12.5dpc  922 0.0 
gb W67038.1 E13.5-14.5dpc total fetus  865 0.0 
gb CX208189.1 Lateral wall of lateral ventricle 787 0.0 
gb AI845825.1 Pineal gland  751 0.0 
gb AI604846.1 E13.5-14.5 dpc total fetus 738 0.0 
gb BE652808.1 Pineal gland 722 0.0 
gb W42249.1 E19.5 dpc total fetus  679 0.0 
emb CR757674.1 Muscle 666 0.0 
 
dpc, days post-conception; E, embryo; EST, expressed-sequence tag;  
Supplementary Table II: Reactivity of rat mAbs against recombinant and endogenous 
mouse S5D-SRCRB protein. 
 
 Recombinant Tissue-expressed 
Hybridoma IP ELISA WB IP WB IHC 
1H11.A8.G2 + + + - + + 
5E12.G3.B1 + + + - + - 
7G4.E1.H7 + + + - + - 
8F4.F3.F9 + + + - + - 
4D11.A2.H4 + + + - + + 
5B7.B8.A1 + + + - + - 
8C4.D6.C9 + + + - + - 
 
The recombinant protein comes from serum-free supernatants of HEK293-EBNA 
transfectants expressing a C-terminal HA-tagged mouse S5D-SRCRB protein. The 
tissue expressed protein comes from RIPA buffer solubilizates of mouse testis. IP, 
Immunoprecipitation. WB, Western blot. IHC, Immunohistochemistry. 
 
